Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Emergent BioSolutions Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Pharmaceutical Preparations
Prev close 6.35 · gapped above the open, then crossed back over prior close. High/low 6.43 at 12:15 pm ET, 6.25 at 9:45 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In 2023, we entered into an agreement with Emergent BioSolutions (Emergent) to provide development and manufacturing services to produce certain Emergent bulk drug substances.”
FILING10-K0001125345-26-000017cik 0001125345disclosed by MGNX
“The Emergent Agreements contemplate that we will enter into one or more binding Master Manufacturing Services Agreements, whereby Emergent will provide contract development and manufacturing services to produce our fully-human polyclonal antibody products.”
FILING10-K0001833214-26-000003cik 0001833214disclosed by SABS
“For example, in July 2023, we were awarded a 10-year contract by BARDA for the advanced development, manufacturing scale-up, and procurement of Ebanga TM (ansuvimab-zykl) treatment for Ebola.”
FILING10-K0001367644-26-000015cik 0001367644
“In February 2025, Bavarian Nordic announced that the FDA approved CHIKV VLP under the Priority Review, which triggered a $30.0 million development milestone payment to the Company.”
FILING10-K0001367644-26-000015cik 0001367644
“In July 2024, the Company entered into the Stock and Asset Purchase Agreement (the "RSDL ® Agreement") with SERB Pharmaceuticals, through its wholly owned subsidiary BTG International Inc. (collectively, "SERB"), pursuant to which, among other things, the Company sold its worldwide rights to RSDL ® , to SERB (the "RSDL ® Transaction").”
FILING10-K0001367644-26-000015cik 0001367644
“The U.S. government ("USG") is the largest purchaser of our Government - MCM products and primarily purchases our products for the Strategic National Stockpile, a national repository of medical countermeasures including critical antibiotics, vaccines, chemical antidotes, antitoxins, and other critical medical supplies.”
FILING10-K0001367644-26-000015cik 0001367644
“Compliance with reporting and other requirements of these federal programs is a pre-condition to: (i) the availability of federal funds to pay for our products under Medicaid and Medicare Part B; and (ii) procurement of our products by the Department of Veterans Affairs ("DVA"), and by covered entities under the 340B/PHS program.”
FILING10-K0001367644-26-000015cik 0001367644
“The decrease was due to lower volumes of CYFENDUS ® sales to the USG and international customers, primarily due to the impact of timing, partially offset by increases in ANTHRASIL ® sales to the Canadian government and BioThrax ® sales to foreign governments.”
FILING10-K0001367644-26-000015cik 0001367644
“Our current procurement contracts with the HHS and the DoW are generally fixed price contracts.”
FILING10-K0001367644-26-000015cik 0001367644
“In addition, for the "Big Four" federal agencies—the DVA, the DoW, the PHS (including the Indian Health Service), and the Coast Guard—we must make covered drugs available at pricing that is capped at the statutory federal ceiling price ("FCP").”
FILING10-K0001367644-26-000015cik 0001367644
“In addition, for the "Big Four" federal agencies—the DVA, the DoW, the PHS (including the Indian Health Service), and the Coast Guard—we must make covered drugs available at pricing that is capped at the statutory federal ceiling price ("FCP").”
FILING10-K0001367644-26-000015cik 0001367644
“If priorities for the Strategic National Stockpile ("SNS") change generally, or as a result of the conclusion of the USG's audit of the SNS, or with respect to the level of procurement of our anthrax vaccines, funding to procure future doses of CYFENDUS ® or BioThrax ® vaccines may be delayed, limited or not available, BARDA may never complete the anticipated full transition to stockpiling CYFENDUS ® in support of anthrax preparedness, and our future business, financial condition, operating results and cash flows could be materially harmed.”
FILING10-K0001367644-26-000015cik 0001367644
“The decrease was primarily attributable to the one time $50.0 million arbitration settlement with Janssen related to the 2022 termination of the Janssen Agreement (the "Settlement Agreement"), which was paid in 2024, coupled with lower revenue from the Company's Camden facility in the current year, which was sold to Bora in the third quarter of 2024, partially offset by an increase in production at the Company's Winnipeg facility.”
FILING10-K0001367644-26-000015cik 0001367644
“In January 2025, the Company announced an agreement with Hikma Pharmaceuticals Inc. ("Hikma") in which the Company obtained exclusive commercial rights for product sales and marketing in the United States and Canada to Hikma's KLOXXADO ® (naloxone HCl) Nasal Spray, an 8 mg naloxone agent.”
FILING10-K0001367644-26-000015cik 0001367644
Watchlist prices, news filtered to it, and its next report on your desk.
Emergent BioSolutions Inc. has 2 disclosed suppliers and 12 disclosed customers. Each one is named in an SEC filing, either Emergent BioSolutions Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
EBS (Emergent BioSolutions Inc.) has 2 disclosed suppliers and 12 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: MGNX −3.57%, in healthcare.